| Management of the extremely preterm infant: is the replacement of estradiol and progesterone beneficial? | |
| | |
MedLine Citation:
|
PMID: 11688594 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
This review presents data to suggest that postnatal estradiol and progesterone replacement therapy may be beneficial in preterm infants. During pregnancy, maternal plasma levels of estradiol and progesterone increase up to 100-fold compared to the nonpregnant status. The fetus is also exposed to these increasing hormone levels. After delivery, estradiol and progesterone levels drop by a factor of 100 within 1 day. Whereas this is a physiological condition for an infant born at term, preterm delivery means withdrawal from the placental supply of these hormones at an earlier developmental stage. Seventy years ago, the idea was raised that preterm infants may benefit from the replacement of estrogens. Studies in which estrogen was injected subcutaneously showed only a slightly better bodyweight gain compared to placebo-treated controls and therefore routine use was not established. The effective treatment of postmenopausal osteoporosis with hormone replacement therapy led to a pilot study of estradiol and progesterone therapy to prevent osteopenia of prematurity. The highest median bone mineral accretion rate was found in the replacement group when the supplementation with calcium and phosphorus was also sufficient. None of the previous studies dealing with estrogen replacement controlled for achieved plasma levels of estradiol in the infants. In our controlled randomised pilot study with 30 preterm infants (15 in each group), we aimed to maintain intra-uterine plasma levels of estradiol and progesterone. Preterm infants with replacement of estradiol and progesterone for 6 weeks postnatally showed trends to higher bone mineral accumulation. In addition, a trend towards a lower incidence of chronic lung disease was found. Neurodevelopmental follow-up showed normal psychomotor development in infants given estradiol and progesterone, whereas the untreated infants (controls) showed a trend towards delayed development. Recent research emphasises that estradiol and progesterone may be important for brain development. Thus, while there is data indicating that postnatal estradiol and progesterone replacement therapy may be beneficial in preterm infants, experience with this new therapy is limited and extensive research is needed to address the potential benefits and to rule out adverse effects. |
| | |
Authors:
|
A Trotter; L Maier; F Pohlandt |
Related Documents
:
|
4052184 - Clinical chorioamnionitis--analysis of the incubation period in patients with preterm p... 19019324 - Therapeutic cerclage may be more efficacious in women who develop cervical insufficienc... 12802374 - Is transvaginal ultrasonography at mid-trimester useful for predicting early spontaneou... 11717634 - Increased tumor necrosis factor-alpha production after lipopolysaccharide stimulation o... 20935314 - Regulation of treatment of infants at the edge of viability in italy: the role of the m... 17450234 - Smoking during pregnancy affects speech-processing ability in newborn infants. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Paediatric drugs Volume: 3 ISSN: 1174-5878 ISO Abbreviation: Paediatr Drugs Publication Date: 2001 |
Date Detail:
|
Created Date: 2001-11-01 Completed Date: 2002-03-19 Revised Date: 2005-11-16 |
Medline Journal Info:
|
Nlm Unique ID: 100883685 Medline TA: Paediatr Drugs Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 629-37 Citation Subset: IM |
Affiliation:
|
Section of Neonatology and Paediatric Critical Care Medicine, Children's Hospital, University of Ulm, Germany. andreas.trotter@medizin.uni-ulm.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Estrogen Replacement Therapy* Estrogens / blood, pharmacokinetics, therapeutic use* Humans Infant, Newborn Infant, Premature / physiology* Progesterone / blood, pharmacokinetics, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Estrogens; 57-83-0/Progesterone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Unilateral spatial neglect.
Next Document: The role of antibacterial therapy of acute otitis media in promoting drug resistance.